Advances in the immunopathogenesis of pulmonary tuberculosis

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 3, 2001, Pages 116-123

  Rook, Graham A W ^a   Zumla, Alimuddin ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL SURVIVAL; GENETIC MANIPULATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; INFECTION CONTROL; LIPID METABOLISM; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0034996610     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200105000-00002     Document Type: Review

References (68)

1. 1 Wayne LG: Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis 1994, 13:908-914.
2. 2 Dolin PJ, Raviglione MC, Kochi A: Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994, 72:213-220.
3. 3 van Rie A, Warren R, Richardson M, et al.: Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999, 341:1174-1179.
4. 4 Fine PE, Small PM: Exogenous reinfection in tuberculosis. N Engl J Med 1999, 341:1226-1227.
5. 5 Dickinson JM, Mitchison DA: Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981, 123:367-371.
6. 6 Balasubramanian V, Wiegeshaus EH, Taylor BT, et al.: Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 1994, 75:168-178.
7. 7 Opie EL, Aronson JD: Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 1927, 4:1-21.
8. 8 Hernandez-Pando R, Jeyanathan M, Mengistu G, et al.. Persistence of DNA from M. tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000, 356:2133-2138. Uses conventional and in situ polymerase chain reaction (PCR) to reveal the presence of DNA from M. tuberculosis in histopathologically normal lung tissue from Ethiopian and Mexican subjects who died of other causes. The cells containing the bacteria include type II pneumocytes, endothelial cells and fibroblasts. All samples from Norwegian controls were negative; there has been no community transmission of tuberculosis in Norway fro several decades.
9. 9 Glickman MS, Cox JS, Jacobs WR Jr: A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000, 5:717-727.
10. 10 McKinney JD, zu Bentrup KH, Munoz-Elias EJ, et al.: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406:735-738. Disruption of the isocitrate lyase gene attenuated bacterial persistence without affecting bacterial growth during the acute phase of infection. Virulence of the strain was restored in IFNγ knockout mice.
11. 11 Zimhony O, Cox JS, Welch JT, et al.: Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 2000, 6:1043-1047. This is the first time that the target molecule of pyrazinamide has been identified.
12. 12 Cox JS, Chen B, McNeil M, et al.: Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999, 402:79-83. M. tuberculosis mutants in which the gene for phthiocerol dimycocerosate has been disrupted grow normally in most tissues, but cannot grow in the lung.
13. 13 Wei J, Dahl JL, Moulder JW, et al.: Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol 2000, 182:377-384.
14. 14 Miller BH, Shinnick TM: Evaluation of Mycobacterium tuberculosis genes involved in resistance to killing by human macrophages. Infect Immun 2000, 68:387-390.
15. 15 Brosch R, Gordon SV, Pym A, et al.: Comparative genomics of the mycobacteria. Int J Med Microbiol 2000, 290:143-152. A valuable review of this area.
16. 16 Dalton DK, Haynes L, Chu CQ, et al.: Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J Exp Med 2000, 192:117-122.
17. 17 Kremer L, Estaquier J, Wolowczuk I, et al.: Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice. Infect Immun 2000, 68:4264-4273. This paper studies the role of T cell apoptosis during mycobacterial infection in susceptible mice. There is TNF-mediated apoptosis of both CD4+ and CD8+ T cells, and Fas-FasL-mediated apoptosis of CD4+ T cells.
18. 18 Watson VE, Hill LL, Owen-Schaub L, et al.: Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology. J Pathol 2000, 190:211-220. Following infection with M. tuberculosis A/J mice develop progressive interstitial pneumonitis, while C57BL/6 form granulomata. Apoptosis was seen in both strains, but differences in its efficiency may partially account for the different immunopathology.
19. 19 Das G, Vohra H, Saha B, et al.: Apoptosis of Th1-like cells in experimental tuberculosis (TB). Clin Exp Immunol 1999, 115:324-328.
20. 20 Hirsch CS, Toossi Z, Vanham G, et al.: Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999, 179:945-953.
21. 21 Maiti D, Bhattacharyya A, Basu J: Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2000, 276:329-333.
22. 22 Rojas M, Garcia LF, Nigou J, et al.: Mannosylated lipoarabinomannan Mycobacterium tuberculosis-induced macrophage apoptosis by altering Ca+2-dependent cell signaling. J Infect Dis 2000, 182:240-251.
23. 23 Fratazzi C, Arbeit RD, Carini C, et al.: Macrophage apoptosis in mycobacterial infections. J Leukoc Biol 1999, 66:763-764.
24. 24 Mustafa T, Phyu S, Nilsen R, et al.: Increased expression of Fas ligand on Mycobacterium tuberculosis-infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation 1999, 23:507-521.
25. 25 Noss EH, Harding CV, Boom WH: Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. Cell Immunol 2000, 201:63-74.
26. 26 Teitelbaum R, Cammer M, Maitland ML, et al.: Mycobacterial infection of macrophages results in membrane-permeable phagosomes. Proc Natl Acad Sci USA 1999, 96:15190-15195.
27. 27 Fayyazi A, Eichmeyer B, Soruri A, et al.: Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol 2000, 191:417-425. A histopathologic study of caseous human lung, using in situ techniques to study molecules involved in apoptosis. The results suggest that caseation is associated with apoptosis of macrophages and T lymphocytes, a lack of bcl-2 and an abundance of bax.
28. 28 Bellamy R: Identifying genetic susceptibility factors for tuberculosis in Africans: a combined approach using a candidate gene study and a genome-wide screen. Clin Sci (Colch) 2000, 98:245-250.
29. 29 Blackwell JM, Searle S: Genetic regulation of macrophage activation: understanding the function of Nramp1 (-Ity/Lsh/Bcg). Immunol Lett 1999, 65:73-80.
30. 30 Wilkinson RJ, Llewelyn M, Toossi Z, et al.: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000, 355:618-621.
31. 31 Hernandez-Pando R, Pavon L, Arriaga K, et al.: Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect Immun 1997, 65:3317-3327.
32. 32 Lindbiad EB, Elhay MJ, Silva R, et al.: Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997, 65:623-629.
33. 33 Seah GT, Rook GA: A sensitive, non-radioactive quantitative method for measuring IL-4 and IL-4delta2 mRNA in unstimulated cells from multiple clinical samples, using nested RT-PCR. J Immunol Methods 1999, 228:139-149.
34. 34 Atamas SP, Yurovsky VV, Wise R, et al.: Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42:1168-1179.
35. 35 Seah GT, Scott GM, Rook GA: Type 2 cytokine gene activation and its relation to extent of disease in patients with tuberculosis. J Infect Dis 2000, 181:385-389. Using a sensitive quantitative nested RT-PCR, that for the first time in TB research, distinguishes between IL-4 and the IL-4 splice variant (IL-4δ2), this paper shows that there is a massive increase in expression of IL-4 and IL-13 in the peripheral blood mononuclear cells of TB patients, which correlates with serum IgE and with lung damage. The reasons for the failure of some previous authors to identify these changes are discussed in full.
36. 36 Seah GT, Rook GAW: High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested RT-PCR: correlations with serum IgE levels. Scand J Infect Dis 2000, 33:106-109.
37. 37 van Crevel R, Karyadi E, Preyers F, et al.: Increased Production of Interleukin 4 by CD4+ and CD8+ T Cells from Patients with Tuberculosis Is Related to the Presence of Pulmonary Cavities. J Infect Dis 2000, 181:1194-1197. In striking agreement with Seah et al. [35••], these authors show that patients have a striking increase in production of IL-4 in CD4+ and CD8+ T cells. Expression of IL-4 was especially elevated in patients with cavitatory TB.
38. 38 Fenhalls G, Wong A, Bezuidenhout J, et al.: In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 2000, 68:2827-2836. In situ methods were applied to human lung biopsies. These methods are appropriate for use with low copy number mRNAs such as IL-4, which was conspicuously present in three of five patients. The possible sequence of events is discussed.
39. 39 Baker RW, Walker BR, Shaw RJ, et al.: Increased Cortisol. Cortisone ratio in acute pulmonary tuberculosis. Am J Respir Crit Care Med 2000, 162:1641-1647. Inactive cortisone is locally converted to active cortisol in the lungs of TB patients. Thus local cortisol levels cannot be predicted from plasma levels, and their increase may contribute to the shift to Th2. This most detailed study of the hypothalamo-pituitary-adrenal (HPA) axis in TB has also revealed that the HPA axis is otherwise normal if the patients are allowed to acclimatize to hospital conditions, and not given treatment. Many previous studies have been detecting effects secondary to stress and rifampicin.
40. 40 Rook G, Baker R, Walker B, et al.: Local regulation of glucocorticoid activity in sites of inflammation; insights from the study of tuberculosis. Ann NY Acad Sci 2000, 917:913-922.
41. 41 Escher G, Galli E, Vishwanath BS, et al.: Tumour necrosis factor α and interleukin 1β enhance the cortisone/cortisol shuttle. J Exp Med 1997, 186:189-198.
42. 42 Pathan AA, Wilkinson KA, Wilkinson RJ, et al.: High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur J Immunol 2000, 30:2713-2721.
43. 43 Cho S, Mehra V, Thoma-Uszynski S, et al.: Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci USA 2000, 97:12210-12215. Human CD8+ T lymphocytes can not only recognize and lyse infected macrophages, but also cause death of the contained bacteria.
44. 44 Silva CL, Lowrie DB: Identification and characterization of murine cytotoxic T cells that Mycobacterium tuberculosis. Infect Immun 2000, 68:3269-3274.
45. 45 Krensky AM: Granulysin: a novel antimicrobial peptide of cytolytic T lymphocytes and natural killer cells. Biochem Pharmacol 2000, 59:317-320. A fascinating review of the biology and evolutionary relationships of granulysin, which is probably the major mechanism that allows CD8+ T cells ta kill M. tuberculosis.
46. 46 D'Souza S, Denis O, Scorza T, et al.: CD4+ T cells contain Mycobacterium tuberculosis infection in the absence of CD8+ T cells in mice vaccinated with DNA encoding Ag85A. Eur J Immunol 2000, 30:2455-2459.
47. 47 Scanga CA, Mohan VP, Yu K, et al.: Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of IFN gamma and nitric oxide synthase 2. J Exp Med 2000, 192:347-358.
48. 48 Moody DB, Ulrichs T, Muhlecker W, et al.: CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000, 404:884-888.
49. 49 Sugita M, van Der Wel N, Rogers RA, et al.: CD1c molecules broadly survey the endocytic system. Proc Natl Acad Sci USA 2000, 97:8445-8450.
50. 50 Schaible UE, Hagens K, Fischer K, et al.: Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells. J Immunol 2000, 164:4843-4852.
51. 51 Dieli F, Troye-Blomberg M, Ivanyi J, et al.: Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol 2000, 30:1512-1519.
52. 52 Behr Perst SI, Munk ME, Schaberg T, et al.: Phenotypically activated gamma/delta T lymphocytes in the peripheral blood of patients with tuberculosis. J Infect Dis 1999, 180:141-149.
53. 53 Dieli F, Sireci G, Di SC, et al.: Ligand-specific alpha/beta and gamma/delta T cell responses in childhood tuberculosis. J Infect Dis 2000, 181:294-301.
54. 54 Brandt L, Elhay M, Rosenkrands I, et al.: ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000, 68:791-795.
55. 55 Stanford JL, Onyebujoh PC, Rook GAW, et al.: Old plague, new plague and a treatment for both? AIDS 1993, 7:1275-1277.
56. 56 Holland SM: Cytokine therapy of mycobacterial infections. Adv Intern Med 2000, 45:431-452.
57. 57 Hernandez-Pando R, Pavon L, Orozco EH, et al.: Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in Balb/c mice. Immunology 2000, 100:391-398.
58. 58 Turner J, Rhoades ER, Keen M, et al.: Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000, 68:1706-1709.
59. 59 Rook GAW, Hernandez-Pando R: The pathogenesis of tuberculosis. Annu Rev Microbiol 1996, 50:259-284.
60. 60 Lowrie DB, Silva CL: Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 2000, 18:1712-1716.
61. 61 Lowrie DB, Tascon RE, Bonato VL, et al.: Therapy of tuberculosis in mice by DNA vaccination. Nature 1999, 400:269-271.
62. 62 Turner OC, Roberts AD, Frank AA, et al.: Lack of protection in mice and necrotizing broncho-interstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect Immun 2000, 68:3674-3679.
63. 63 Wang CC, Rook GAW: Inhibition of an established allergic response to ovalbumin in Balb/c mice by killed Mycobacterium vaccae. Immunology 1998, 93:307-313.
64. 64 Camporota L, Corkhill A, Long H, et al.: Effects of intradermal Mycobacterium vaccae on allergen-induced airway responses and IL-5 generation by PBMC in mild to moderate asthma. Am J Respir Crit Care Med 2000, 161:477.
65. 65 Johnson JL, Kamya RM, Okwera A, et al.: Randomised controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis 2000, 181:1304-1312.
66. 66 Waddell RD, Chintu C, Lein AD, et al.: Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccine for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000, 30(suppl 3):309-315.
67. 67 Phyu S, Mustafa T, Hofstad T, et al.: A mouse model for latent tuberculosis. Scand J Infect Dis 1998, 30:59-68.
68. 68 Griffin JF, Mackintosh CG, Slobbe L, et al.: Vaccine protocols to optimize the protective efficacy of BCG. Tuber Lung Dis 1999, 79:135-143.